Establishment and Validation of a Risk Prediction Model for Mortality in Patients with Acinetobacter baumannii Infection: A Retrospective Study

References

• Ciginskiene A, Dambrauskiene A, Rello J, et al. Ventilator-associated pneumonia due to drug-resistant Acinetobacter baumannii: risk factors and mortality relation with resistance profiles, and independent predictors of In-hospital mortality. Medicina. 2019;55(2):49. doi:10.3390/medicina55020049
   PubMedGoogle Scholar
• Phitchayapak W, Komwit S, Kamonnut S. Novel Autographiviridae phage and its combined effect with tigecycline in controlling multidrug-resistant Acinetobacter baumannii-associated skin and soft tissue infections. Viruses. 2022;14(2):194. doi:10.3390/v14020194
   PubMed Web of Science ®Google Scholar
• Rudzani CM, Susan TM, Angela D, et al. Culture-confirmed neonatal bloodstream infections and meningitis in South Africa 2014–19: a cross-sectional study. Lancet Glob Health. 2022;10(8):e1170–e1178. doi:10.1016/S2214-109X(22)00246-7
   PubMed Web of Science ®Google Scholar
• Filiz K, Aysegul SK, Kubra DO, et al. Clinical features of post-operative nosocomial meningitis in adults and evaluation of efficiency of intrathecal treatment. Surg Infect. 2021;22(10):1059–1063. doi:10.1089/sur.2021.024
   PubMed Web of Science ®Google Scholar
• Choe YJ, Lee HJ, Choi EH. Risk factors for mortality in children with Acinetobacter baumannii bacteremia in South Korea: the role of carbapenem resistance. Microb Drug Resist. 2019;25(8):1210–1218. doi:10.1089/mdr.2018.0465
   PubMed Web of Science ®Google Scholar
• Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist. 2018;11:1249–1260. doi:10.2147/IDR.S166750
   PubMed Web of Science ®Google Scholar
• Zhou H, Yao Y, Zhu BQ, Ren DH. Risk factors for acquisition and mortality of multidrug-resistant Acinetobacter baumannii bacteremia: a retrospective study from a Chinese hospital. Medicine. 2019;98(13):e14937. doi:10.1097/MD.0000000000014937
   PubMed Web of Science ®Google Scholar
• Montrucchio G, Costamagna A, Pierani T, et al. Bloodstream infections caused by carbapenem-resistant pathogens in intensive care units: risk factors analysis and proposal of a prognostic score. Pathogens. 2022;11(7):718. doi:10.3390/pathogens11070718
   PubMed Web of Science ®Google Scholar
• Boral B, Unaldi O, Ergin A, Durmaz R, Eser ÖK. A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features. Ann Clin MicrobiolAntimicrob. 2019;18(1):19. doi:10.1186/s12941-019-0319-8
   PubMedGoogle Scholar
• Anggraini D, Santosaningsih D, Endraswari PD, et al. Multicenter study of the risk factors and outcomes of bloodstream infections caused by carbapenem-non-susceptible Acinetobacter baumannii in Indonesia. Trop Med Infect Dis. 2022;7(8):161. doi:10.3390/tropicalmed7080161
   PubMedGoogle Scholar
• Lee CM, Kim CJ, Kim SE, et al. Risk factors for early mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteraemia. J Glob Antimicrob Resist. 2022;31:45–51. doi:10.1016/j.jgar.2022.08.010
   PubMed Web of Science ®Google Scholar
• Shi N, Kang JB, Sy W, et al. Bacteriological profile and antimicrobial susceptibility patterns of gram-negative bloodstream infection and risk factors associated with mortality and drug resistance: a Retrospective Study from Shanxi, China. Infect Drug Resist. 2022;15:3561–3578. doi:10.2147/IDR.S370326
   PubMed Web of Science ®Google Scholar
• Kang JS, Yi JY, Ko MK, et al. Prevalence and risk factors of carbapenem-resistant Enterobacteriaceae acquisition in an emergency intensive care unit in a Tertiary Hospital in Korea: a case-control study. J Korean Med Sci. 2019;34(18):e140. doi:10.3346/jkms.2019.34.e140
   PubMed Web of Science ®Google Scholar
• Lee HY, ShY H, Hsu JF, et al. Risk factors and molecular epidemiology of Acinetobacter baumannii bacteremia in neonates. J Microbiol Immunol Infect. 2018;51(3):367–376. doi:10.1016/j.jmii.2017.07.013
   PubMedGoogle Scholar
• Yonit WW, Daniel T, Alon B, et al. Rate and risk factors for carbapenem resistant Acinetobacter baumannii clinical infections in colonized patients. Isr Med Assoc J. 2022;24(4):235–240.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhao YY, Zheng YH, et al. Development and validation of a model for predicting the risk of death in patients with AcinetobacterbaumanniiInfection: a retrospective study. Infect Drug Resist. 2020;13:2761–2772. e Collection 2020. doi:10.2147/IDR.S253143
   PubMed Web of Science ®Google Scholar
• Rodríguez Del Águila MM, González-Ramírez AR. Sample size calculation. AllergolImmunopathol. 2014;42(5):485--–492.
   Google Scholar
• Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Br J Surg. 2015;102(3):148–158. doi:10.1002/bjs.9736
   PubMed Web of Science ®Google Scholar
• Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332. doi:10.1016/j.ajic.2008.03.002
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Pavlou M, Ambler G, Seaman SR, et al. How to develop a more accurate risk prediction model when there are few events. BMJ. 2015;351:h3868. doi:10.1136/bmj.h3868
   PubMed Web of Science ®Google Scholar
• Pogue JM, Zhou Y, Kanakamedala H, et al. Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019. BMC Infect Dis. 2022;22(1):36. doi:10.1186/s12879-021-07024-4
   PubMed Web of Science ®Google Scholar
• Ju MH, Hou DN, Chen S, et al. Risk factors for mortality in ICU patients with Acinetobacter baumannii ventilator-associated pneumonia: impact of bacterial cytotoxicity. J Thorac Dis. 2018;10(5):2608–2617. doi:10.21037/jtd.2018.04.86
   PubMed Web of Science ®Google Scholar
• Diaa A, Omar AF, Alreesi A, et al. Acinetobacter baumannii infection-related mortality in hospitalized patients: risk factors and potential targets for clinical and antimicrobial stewardship interventions. Antibiotics. 2022;11(8):1086. doi:10.3390/antibiotics11081086
   Google Scholar
• ali A, Nahid CS, Zahra AH, et al. The significant role of carbapenems-resistant AcinetobacterBaumannii in mortality rate of patients with COVID-19. Vacunas. 2022;24(1):13–18.
   PubMedGoogle Scholar
• Cui JW, Li M, Cui JM, et al. The proportion, species distribution and dynamic trends of bloodstream infection cases in a tertiary hospital in China, 2010–2019. Infection. 2022;50(1):121–130. doi:10.1007/s15010-021-01649-y
   PubMed Web of Science ®Google Scholar
• Hu F, Guo Y, Yang Y; China Antimicrobial Surveillance Network (CHINET) Study Group. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38(12):2275–2281. doi:10.1007/s10096-019-03673-1
   PubMed Web of Science ®Google Scholar
• Hu WX, Xie SL, Yu F, et al. Characteristics of pathogens and mortality predictors of older Chinese patients with nosocomial urinary tract infections. GeriatrGerontol Int. 2019;19(6):541–546. doi:10.1111/ggi.13661
   PubMed Web of Science ®Google Scholar